MR cholangiopancreatography in children: Feasibility, safety, and initial experience

Lisa Delaney, Kimberly E. Applegate, Boaz Karmazyn, M. Akisik, S. Gregory Jennings

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background: The indications for MR cholangiopancreatography (MRCP) in children, and its safety and findings, might differ from those in adults and are not well described. Objective: To investigate the safety, feasibility, and accuracy of MRCP in children. Materials and methods: We reviewed all prospective MRCP reports, noting the indication, the use of secretin, endoscopic retrograde cholangiopancreatography (ERCP) findings, and patient outcomes. Two readers reviewed each MRCP study by consensus to rate duct visualization and compare pancreatic duct sizes before and after secretin administration (paired t-test). The likelihood of a normal versus an abnormal MRCP study was compared by gender, pancreatitis as the primary indication, secretin use, and whether ERCP was performed (Fisher's exact test), as well as age (t-test). Results: A total of 85 MRCP studies were performed in children (mean age 10.3 years), most commonly for evaluation of pancreatitis (n=47, 55%); 41 (48%) used secretin and 39 (46%) used a negative oral contrast agent. Of the 85 studies, 72 (85%) had excellent image quality and 43 were normal. ERCP was performed after 16 of the 85 MRCP studies (19%); the diagnoses were concordant with those of MRCP in 13 (81%). There were 42 abnormal MRCP studies, and these were more likely to be in girls (P=0.03) and in children who had undergone ERCP (P<0.01). Secretin and the negative oral contrast agent were well-tolerated. Secretin improved duct visualization (P<0.001). Conclusion: MRCP safely and accurately depicted pancreaticobiliary anatomy in children. The use of secretin improved visualization of the pancreatic duct.

Original languageEnglish
Pages (from-to)64-75
Number of pages12
JournalPediatric Radiology
Volume38
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Secretin
Safety
Endoscopic Retrograde Cholangiopancreatography
Pancreatic Ducts
Pancreatitis
Contrast Media
Anatomy

Keywords

  • Children
  • Magnetic resonance cholangiopancreatography
  • Pancreatitis
  • Secretin

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pediatrics, Perinatology, and Child Health
  • Radiological and Ultrasound Technology

Cite this

MR cholangiopancreatography in children : Feasibility, safety, and initial experience. / Delaney, Lisa; Applegate, Kimberly E.; Karmazyn, Boaz; Akisik, M.; Jennings, S. Gregory.

In: Pediatric Radiology, Vol. 38, No. 1, 01.2008, p. 64-75.

Research output: Contribution to journalArticle

Delaney, Lisa ; Applegate, Kimberly E. ; Karmazyn, Boaz ; Akisik, M. ; Jennings, S. Gregory. / MR cholangiopancreatography in children : Feasibility, safety, and initial experience. In: Pediatric Radiology. 2008 ; Vol. 38, No. 1. pp. 64-75.
@article{39714f00afd64397852b08299494ec3f,
title = "MR cholangiopancreatography in children: Feasibility, safety, and initial experience",
abstract = "Background: The indications for MR cholangiopancreatography (MRCP) in children, and its safety and findings, might differ from those in adults and are not well described. Objective: To investigate the safety, feasibility, and accuracy of MRCP in children. Materials and methods: We reviewed all prospective MRCP reports, noting the indication, the use of secretin, endoscopic retrograde cholangiopancreatography (ERCP) findings, and patient outcomes. Two readers reviewed each MRCP study by consensus to rate duct visualization and compare pancreatic duct sizes before and after secretin administration (paired t-test). The likelihood of a normal versus an abnormal MRCP study was compared by gender, pancreatitis as the primary indication, secretin use, and whether ERCP was performed (Fisher's exact test), as well as age (t-test). Results: A total of 85 MRCP studies were performed in children (mean age 10.3 years), most commonly for evaluation of pancreatitis (n=47, 55{\%}); 41 (48{\%}) used secretin and 39 (46{\%}) used a negative oral contrast agent. Of the 85 studies, 72 (85{\%}) had excellent image quality and 43 were normal. ERCP was performed after 16 of the 85 MRCP studies (19{\%}); the diagnoses were concordant with those of MRCP in 13 (81{\%}). There were 42 abnormal MRCP studies, and these were more likely to be in girls (P=0.03) and in children who had undergone ERCP (P<0.01). Secretin and the negative oral contrast agent were well-tolerated. Secretin improved duct visualization (P<0.001). Conclusion: MRCP safely and accurately depicted pancreaticobiliary anatomy in children. The use of secretin improved visualization of the pancreatic duct.",
keywords = "Children, Magnetic resonance cholangiopancreatography, Pancreatitis, Secretin",
author = "Lisa Delaney and Applegate, {Kimberly E.} and Boaz Karmazyn and M. Akisik and Jennings, {S. Gregory}",
year = "2008",
month = "1",
doi = "10.1007/s00247-007-0644-5",
language = "English",
volume = "38",
pages = "64--75",
journal = "Pediatric Radiology",
issn = "0301-0449",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - MR cholangiopancreatography in children

T2 - Feasibility, safety, and initial experience

AU - Delaney, Lisa

AU - Applegate, Kimberly E.

AU - Karmazyn, Boaz

AU - Akisik, M.

AU - Jennings, S. Gregory

PY - 2008/1

Y1 - 2008/1

N2 - Background: The indications for MR cholangiopancreatography (MRCP) in children, and its safety and findings, might differ from those in adults and are not well described. Objective: To investigate the safety, feasibility, and accuracy of MRCP in children. Materials and methods: We reviewed all prospective MRCP reports, noting the indication, the use of secretin, endoscopic retrograde cholangiopancreatography (ERCP) findings, and patient outcomes. Two readers reviewed each MRCP study by consensus to rate duct visualization and compare pancreatic duct sizes before and after secretin administration (paired t-test). The likelihood of a normal versus an abnormal MRCP study was compared by gender, pancreatitis as the primary indication, secretin use, and whether ERCP was performed (Fisher's exact test), as well as age (t-test). Results: A total of 85 MRCP studies were performed in children (mean age 10.3 years), most commonly for evaluation of pancreatitis (n=47, 55%); 41 (48%) used secretin and 39 (46%) used a negative oral contrast agent. Of the 85 studies, 72 (85%) had excellent image quality and 43 were normal. ERCP was performed after 16 of the 85 MRCP studies (19%); the diagnoses were concordant with those of MRCP in 13 (81%). There were 42 abnormal MRCP studies, and these were more likely to be in girls (P=0.03) and in children who had undergone ERCP (P<0.01). Secretin and the negative oral contrast agent were well-tolerated. Secretin improved duct visualization (P<0.001). Conclusion: MRCP safely and accurately depicted pancreaticobiliary anatomy in children. The use of secretin improved visualization of the pancreatic duct.

AB - Background: The indications for MR cholangiopancreatography (MRCP) in children, and its safety and findings, might differ from those in adults and are not well described. Objective: To investigate the safety, feasibility, and accuracy of MRCP in children. Materials and methods: We reviewed all prospective MRCP reports, noting the indication, the use of secretin, endoscopic retrograde cholangiopancreatography (ERCP) findings, and patient outcomes. Two readers reviewed each MRCP study by consensus to rate duct visualization and compare pancreatic duct sizes before and after secretin administration (paired t-test). The likelihood of a normal versus an abnormal MRCP study was compared by gender, pancreatitis as the primary indication, secretin use, and whether ERCP was performed (Fisher's exact test), as well as age (t-test). Results: A total of 85 MRCP studies were performed in children (mean age 10.3 years), most commonly for evaluation of pancreatitis (n=47, 55%); 41 (48%) used secretin and 39 (46%) used a negative oral contrast agent. Of the 85 studies, 72 (85%) had excellent image quality and 43 were normal. ERCP was performed after 16 of the 85 MRCP studies (19%); the diagnoses were concordant with those of MRCP in 13 (81%). There were 42 abnormal MRCP studies, and these were more likely to be in girls (P=0.03) and in children who had undergone ERCP (P<0.01). Secretin and the negative oral contrast agent were well-tolerated. Secretin improved duct visualization (P<0.001). Conclusion: MRCP safely and accurately depicted pancreaticobiliary anatomy in children. The use of secretin improved visualization of the pancreatic duct.

KW - Children

KW - Magnetic resonance cholangiopancreatography

KW - Pancreatitis

KW - Secretin

UR - http://www.scopus.com/inward/record.url?scp=36448933143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448933143&partnerID=8YFLogxK

U2 - 10.1007/s00247-007-0644-5

DO - 10.1007/s00247-007-0644-5

M3 - Article

C2 - 17999059

AN - SCOPUS:36448933143

VL - 38

SP - 64

EP - 75

JO - Pediatric Radiology

JF - Pediatric Radiology

SN - 0301-0449

IS - 1

ER -